Arizona Tribune - Boulevard

NYSE - LSE

CMSC	-0.53%	21.93	$
RBGPF	5.69%	65	$
RYCEF	2.12%	18.39	$
BCE	-1.22%	22.92	$
BCC	1.56%	81.02	$
RIO	-1.46%	93.74	$
NGG	-0.49%	83.01	$
CMSD	-0.73%	21.77	$
GSK	1.16%	52.5	$
VOD	0.22%	13.89	$
JRI	1.64%	12.79	$
RELX	1.34%	31.34	$
BP	-1.59%	37.13	$
BTI	0.45%	62.76	$
AZN	1.45%	188.41	$

Featured

Israelis, Palestinians torn over sacred shrine in city of Hebron

For Israeli settler Nitzan, Hebron's Old City and its sacred Cave of the Patriarchs shrine are a must-see for all of humanity, but for Palestinian Issa Amro, it has become a symbol of Israel's expanding grip on the city.

Critical rescue window closing in Venezuela as quake death toll nears 1,500

Emergency teams with rescue dogs were searching Sunday for any remaining survivors of powerful twin earthquakes that struck Venezuela, where the death toll has surpassed 1,450 and nearly 200 building have completely collapsed.

Last news

Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026

DENVER, CO / ACCESS Newswire / May 6, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its third quarter of fiscal 2026, after the market close on Wednesday, May 13, 2026. The Company has scheduled a conference call and webcast that same day, Wednesday, May 13, 2026, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.

Vanta Announces Closing of Second Tranche of Private Placement for Aggregate Gross Proceeds of $1 Million

VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Vanta Holdings Inc. (CSE:VNTA)(OTC:VNTXF)(FSE:7BC, WKN:A4205J) ("Vanta" or the "Company"), a consumer health sciences company and parent of the Vanta premium hydration and longevity brand, announces that, further to its news release dated May 5, 2026, the Company has closed the second tranche (the "Second Tranche") of its previously announced non-brokered private placement (the "Private Placement").

Avel eCare Hosts National Emergency Airway Course, Earning Top Marks from Clinicians Across the Country

Advanced training draws national participants and strengthens lifesaving skills for emergency providers.

Wipeboard Launches AI Creative Ideation Add-On, Bringing AI-Powered Brainstorming Directly Into Team Project Boards

New $19/month add-on generates idea cards from user challenges and converts brainstorm sessions into live project tasks with one click

Cosmos Health Introduces Fort18 in the United States - A Men's Sexual Stamina Supplement Expanding the 18 Series into Men's Wellness

Science-based men's wellness: Fort18™ is formulated with a proprietary five-ingredient botanical blend intended to support men's sexual staminaLarge and growing market: The U.S. sexual health supplement market is projected to reach $1.93 billion by 2030Expanding the 18 Series: Fort18™ joins Noor18™, Liv18™, and Cur18™ - advancing the target of 18 science-based products spanning key health categories

Nurses Week Report: FBI Cyber Warning Puts Hospital Nurses' Downtime Readiness in Focus

Black Book Research six month survey of 480 registered nurses finds 78% experienced an unplanned clinical technology outage in the past year, 64% report no recent realistic downtime drill, and 62% lack confidence administering medications safely without eMAR or barcode scanning

Rythmia Residences Launches in Costa Rica, Introducing a First-of-Its-Kind Conscious Living Community Integrated with the Rythmia Life Advancement Center

TAMARINDO, COSTA RICA / ACCESS Newswire / May 6, 2026 / Rythmia Life Advancement Center, a globally recognized leader in transformational wellness experiences, today announced the official launch of Rythmia Residences, a private luxury residential community designed to integrate world-class wellness into everyday living.

Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)

Pediatric patients with Intestinal Failure (IF) due to MVID, an ultrarare congenital disorder with lethal natural history, that has no available therapies and needs lifelong total Parenteral Support (PS), could benefit from expedited development of oral crofelemer via Breakthrough Therapy DesignationCrofelemer has demonstrated meaningful reductions in weekly PS needs in two pediatric MVID patients with initial results to be presented at ESPGHAN 2026

Dolphin Subsidiary Clients Shape the Summer 2026 Season With Culture-Defining Festivals and Events

NEW YORK, NY / ACCESS Newswire / May 6, 2026 / Leading entertainment marketing and content production company Dolphin (Nasdaq:DLPN) and its marketing division - consisting of marketing and public relations powerhouses 42West, The Door, Shore Fire Media, Elle Communications, Special Projects and The Digital Dept. - is shaping the sights and sounds of summer in 2026 with a full slate of client events and activations. From large-scale, multi-format festivals and conferences to concert series and sporting competitions, the Dolphin companies represent a wide range of clients hosting culture-defining events across the country this summer.

Newsmax Surpasses 25 Million Social Media Followers

Company Sees Record-Breaking Audience Growth in Key Platforms

Dr. Ran Rubinstein Introduces Renuva(R): A Breakthrough Non-Surgical Fat Restoration Treatment in New York and New Jersey

Double board-certified facial plastic surgeon now offers Renuva at Laser & Cosmetic Surgery Specialists in Newburgh, NY and Rubinstein Plastic Surgery Center in Montvale, NJ

Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection

Program Enters Final Stage of Dose OptimizationData Continue to Demonstrate Strong Clinical Activity and Favorable Safety Across an Expanding Frontline Dataset

Amphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care Conference

RANCHO CUCAMONGA, CA / ACCESS Newswire / May 6, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be presenting at the 2026 Bank of America Health Care Conference on Wednesday, May 13, 2026, at 3:00 pm PT. For access to the webcast, visit Amphastar Pharmaceuticals' website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.

InterContinental Hotels Group PLC Announces Transaction in Own Shares - May 06

InterContinental Hotels Group PLC (the "Company")Purchase of own shares

Musk 'was going to hit me,' OpenAI executive says at trial

OpenAI President Greg Brockman told a California jury Tuesday that Elon Musk physically threatened him during a 2017 confrontation, testifying that the billionaire stormed out after he was refused absolute control of the artificial intelligence company.

G7 trade ministers meet, not expected to discuss US tariff threat

G7 trade ministers opened a meeting in Paris on Tuesday to discuss issues including critical minerals, but were not expected to directly address the latest US threat to impose additional tariffs on European vehicles.

German car-ramming suspect had mental health problems: reports

A man suspected of ploughing a car into a crowd in the eastern German city of Leipzig, killing two people, had recently been treated for mental health problems, reports said Tuesday.

China fireworks factory explosion kills 26, injures 61

The death toll from a giant explosion at a fireworks factory in central China rose to 26, with 61 more injured, officials said Tuesday.

Sherlock Holmes fans recreate fateful duel at Swiss falls

Immaculately dressed in Victorian costume, Sherlock Holmes devotees gathered at the Reichenbach Falls in Switzerland to recreate the intrepid detective's fateful duel with his nemesis Professor Moriarty, 135 years on.

Trouble in paradise: Colombia tourist jewel plagued by violence

With snow-capped mountains sweeping down to the turquoise waters of the Caribbean, Sierra Nevada de Santa Marta National Park is one of the jewels in Colombia's tourism crown.

Death toll in Brazil small plane crash rises to three

Three people died and two others were injured Monday after a small plane crashed into a residential building in the major Brazilian city of Belo Horizonte.

Chesapeake Bay Foundation Continues Spreading False Claims in Latest Attack on Atlantic Menhaden Fishery

WASHINGTON, DC / ACCESS Newswire / May 5, 2026 / Just over a month ago, Will Poston of the Chesapeake Bay Foundation once again published false and misleading claims about Virginia's menhaden fishery. Just as CBF did in a March email falsely connecting natural fish die-offs to the menhaden fishery, Poston presents advocacy as science, speculation as fact, and political talking points as settled biology.Poston's piece is built around a series of assertions that cannot stand up to the actual record.

Vanta Announces Closing of First Tranche of Private Placement and Debt Settlement

VANCOUVER, BC / ACCESS Newswire / May 5, 2026 / Vanta Holdings Inc. (CSE:VNTA)(OTC:VNTXF)(FSE:7BC, WKN:A4205J) ("Vanta" or the "Company"), a consumer health sciences company and parent of the Vanta premium hydration and longevity brand, announces that, further to its news releases dated January 29, 2026 and March 25, 2026, the Company has closed the first tranche (the "First Tranche") of its previously announced non-brokered private placement (the "Private Placement") and closed its previously announced debt settlement (the "Debt Settlement"), on the terms described herein.

Onco-Innovations Announces Inka Health Collaborative Research to Advance Oncology Evidence Generation

VANCOUVER, BC / ACCESS Newswire / May 5, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that Inka Health Corp. ("Inka Health"), the Company's wholly owned subsidiary, has started a collaborative research agreement (the "Agreement" or "Project" or "Work") with GlaxoSmithKline LLC ("GSK"). Under the Agreement, Inka Health and GSK intend to collaborate to develop real-world data-driven methodologies aimed at improving the transportability of oncology clinical trial results across broader patient populations, geographies, and healthcare settings, with a view to helping to make clinical evidence more relevant to real-world decision-making.

Big Cannabis Sold You a Lie. Now the Federal Government Is Giving It to Your Grandparents.

Bombshell lawsuits, a European safety bombshell, and a rogue Medicare program converge in the most dangerous moment in American cannabinoid policy history.

Viemed Healthcare Announces First Quarter 2026 Financial Results

LAFAYETTE, LA / ACCESS Newswire / May 5, 2026 / Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and chronic disease management, announced today that it has reported its financial results for the three months ended March 31, 2026, and updated guidance for the full year ending December 31, 2026.

Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update

ICOTYDE™ (icotrokinra) approved by FDA in March for moderate-to-severe plaque psoriasis, triggering a $50 million milestone payment; Protagonist receives tiered royalties of 6% to 10% and is eligible for up to $580 million in future milestone paymentsRusfertide NDA accepted and granted Priority Review by FDA, with a Prescription Drug User Fee Act target action date in the third quarter of 2026Protagonist exercised its rusfertide opt-out right under the Takeda collaboration on April 28, triggering a $200 million opt-out fee payable to the Company; eligible for additional $200 million opt-out and $75 million milestone payments upon NDA approval, sales milestones of up to $775 million and worldwide royalties ranging from 14% to 29%PN-881 (oral IL-17 antagonist peptide) Phase 1 study completion by mid-2026 and Phase 2 initiation anticipated by year-end; PN-477sc and PN-477o (sc and oral triple GLP/GIP/GICG agonist) Phase 1 initiation expected in mid-2026 and Q1 2027, respectivelyCash, cash equivalents and marketable securities of $620 million as of March 31, 2026, anticipated to provide cash runway through at least 2028

TRCP Video Series Is Latest Campaign to Spread Falsehoods About Atlantic Menhaden Fishery

WASHINGTON, D.C. / ACCESS Newswire / May 5, 2026 / A recent video series from the Teddy Roosevelt Conservation Partnership continues the organization's near decade-long practice of spreading misinformation about the Atlantic menhaden fishery. From substituting anecdotes for real science to misidentifying the companies involved in the fishery to mischaracterizing the state of the stock, the videos paint a misleading picture of a sustainable and economically vital fishery.

Eight PLAN C Client Brands Named to the 3AF 2026 Impact 50, Recognizing the Most Influential Advertisers Reaching Asian American Consumers

Gilead, Head & Shoulders, Martell, New York Life, Olay, Old Spice, Secret, and Tide recognized among the top 50 national brands driving authentic engagement with Asian American consumers in 2025

Medical Care Technologies Inc. (OTC PINK:MDCE) Advances AI Platform Accuracy for Early Melanoma Detection

Emerging AI Imaging Capabilities Provide Dynamic Improvements in our Dermatological Analysis Accuracy

Lexaria Updates Progress on Human Study #7

KELOWNA, BC / ACCESS Newswire / May 5, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, provides this update on Human Pilot Study #7 (GLP-1-H26-7) that will evaluate two oral DehydraTECH-semaglutide ("DHT-sema") compositions against Novo Nordisk's® commercially available Wegovy® tablets (the "Study").

MEDIA ADVISORY: Grand Opening and Community Blood Drive Address Critical Local Need

Advanced Health Announces Grand Opening and Community Blood Drive with The Blood Connection on May 19

Arizona Tribune - Boulevard (English)